Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation.
Puig
Noemí
N
Caballero
María D
MD
Alcoceba
Miguel
M
Sebastián
Elena
E
Balanzategui
Ana
A
Sarasquete
María E
ME
García-Sanz
Ramón
R
González-Díaz
Marcos
M
D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014184:Transplantation, Homologous / Q000009:adverse effects*
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab